The FTC Track: Why Your FDA Position Does Not Close Your Exposure

Two agencies, two questions, one catalogue

Most operators in this category eventually get the FDA question roughly right. They stop writing therapeutic language, they position the compounds as research materials, and they put a disclaimer where a reader can find it. Then they assume the compliance work is finished.

It is not finished, because a second agency is asking a different question and does not care how the first one was answered.

The Federal Trade Commission enforces against deceptive advertising. Its authority is independent of whether a product is an approved drug, a research material, or a dietary supplement. A catalogue can be entirely defensible on intended use and still be exposed on substantiation, because the FTC is not asking what the product is. It is asking whether the claims made about it were supported by evidence at the moment they were published.

This is not a legal opinion. It is a reading of primary guidance, linked so every statement can be checked against the source rather than against a summary.

The standard, in the FTC's own words

The governing document is the FTC's Health Products Compliance Guidance. Its statement of the substantiation requirement is direct: claims about the benefits of foods, dietary supplements, drugs and other health-related products require substantiation in the form of competent and reliable scientific evidence.

That phrase, competent and reliable scientific evidence, is the whole standard. It is not a synonym for "we found a study". It describes evidence developed by qualified people using procedures generally accepted in the relevant field, and the guidance evaluates whether the evidence actually supports the claim as it was worded.

Then the guidance narrows it further, and this is the sentence that reshapes what most peptide catalogues are able to say: as a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing to meet the competent and reliable scientific standard.

What that does to a research peptide catalogue

Read that against the actual evidence base for this category.

The overwhelming majority of published work behind research peptides is preclinical. Animal models, cell culture, receptor binding, mechanism studies. That work is genuine science, often careful, sometimes striking. Under the standard above it does not substantiate a benefit claim about a person.

The reason is not that preclinical science is inferior. It is that a claim about what happens in people is a claim about people, and evidence from a rodent tendon or a cultured cell line is evidence about a rodent tendon or a cultured cell line. The gap between those two statements is the entire compliance problem in this category, and it is a gap that no amount of citation density closes.

This produces a counterintuitive result that operators find hard to accept: an article can be scientifically accurate, thoroughly cited, and still constitute an unsubstantiated claim, because accuracy about a study is not substantiation for a statement about a person.

Advertising is broader than you think

The second thing the guidance establishes is scope, and it forecloses the most common workaround.

The guidance defines advertising to refer not only to traditional television, radio, print and internet ads, but also more broadly to the variety of marketing techniques and promotion methods that marketers engage in.

There is no private channel in that definition. A reply in a support ticket is a marketing communication. So is a caption, an email sequence, a creator's video script, a comment left under someone else's post, and what a founder says on a podcast. Operators who carefully police the product page and then answer questions freely in direct messages have not reduced their exposure, they have moved it somewhere that is harder to audit and just as discoverable.

The FTC advertising guide for small business carries the same principle into the endorsement question. What a testimonial conveys to a reasonable reader is the advertiser's claim. A customer saying it is not a defence, and a creator saying it in exchange for a commission is, if anything, worse, because the commercial relationship is exactly what makes it advertising.

Substantiation is held, not assembled

The third principle is about timing, and it is the one that separates a business with a compliance posture from a business with a compliance story.

Substantiation must exist at the time the claim is made. Not at the time a complaint arrives. Not at the time someone asks for it.

The practical consequence is procedural rather than scientific. If a claim goes live and nobody can produce, on that day, the specific evidence supporting the specific wording, then the claim was unsubstantiated when it published, and locating a supporting paper afterwards does not retroactively fix that. It demonstrates that the evidence existed in the world. It does not demonstrate that the business held it.

This is why claim clearance needs a record with a date and an owner attached. Not because a regulator will ask for your internal documentation in that form, but because without it the business genuinely cannot answer the question of what it knew and when.

Comparative and superiority claims

The guidance handles comparisons as their own category, and operators reliably get this wrong in the same way.

A claim that one product is purer, stronger, more bioavailable or better than another requires evidence for the comparison itself. Evidence about each product separately does not aggregate into evidence about the relationship between them. Two certificates of analysis showing 99 percent purity do not substantiate "purest on the market", because that claim is about the market, and nobody tested the market.

The safe version of a comparative claim is usually a factual one. Stating your own measured figure, with the method and the batch, says something true and checkable. Stating that it beats everyone else's says something nobody measured.

Purity and testing claims are factual representations

The most checkable claims on a typical peptide site are the ones about testing, and they sit squarely inside the substantiation standard because they are factual representations rather than opinions.

A stated purity percentage is a claim about a measurement. Third-party tested is a claim about who performed it. Every batch is a claim about universality across production. Each of those attaches to a specific batch rather than to a brand, which means a site-wide figure needs documentation behind every batch it covers.

The failure mode here is not usually dishonesty. It is a claim written once, during launch, that quietly becomes universal as the catalogue grows and the documentation does not keep pace. The claim was true about the first batch and was never revisited.

What the FTC track changes about your operation

Four things follow from the above, and none of them require a lawyer to begin.

• Audit by channel, not by page. If advertising includes support replies and creator scripts, then the compliance surface is every place a human represents the business. Most operators have never looked at their own support macros through this lens.

• Sort claims into factual and benefit. Factual claims about purity, testing and manufacturing need documents. Benefit claims about people need randomized controlled human evidence. They fail in different ways and get fixed differently.

• Date every clearance. A claim with no recorded owner and no review date cannot be shown to have been substantiated when it was made, which is an operational failure independent of whether the claim was ever wrong.

• Report findings in their own terms. A study description that carries its model system is defensible. In a rat model, accelerated tendon healing was observed by the authors is a different sentence from a claim about recovery, and only the first one is supported by the underlying work.

The relationship between the two tracks

The FDA and FTC questions interact in a way worth stating precisely, because operators often assume one subsumes the other.

They do not. Intended use, governed by the Code of Federal Regulations (CFR) at 21 CFR 201.128, determines what your product legally is, and it is established by what you say about it. Substantiation, governed by the FTC guidance, determines whether what you said was supported. A statement can establish an unlawful intended use and be perfectly well substantiated. A different statement can leave intended use untouched and still be deceptive for lack of evidence.

The practical implication is that a claim needs to clear both, in order. First, does saying this establish a therapeutic intended use? Second, if not, is the claim as worded supported by evidence held today? A claim that fails the first test is not rescued by strong evidence, and a claim that passes the first is not finished.

Frequently asked questions

Does the FTC standard apply if we never mention a disease?

Yes. The standard governs health-related benefit claims generally. Avoiding disease language addresses a different problem, which is intended use. A claim about wellness, performance or recovery in a person is still a health-related benefit claim requiring substantiation.

We cite peer-reviewed studies. Is that substantiation?

Not automatically. The question is whether the cited work supports the claim as worded, at the standard the guidance describes. A citation to preclinical work attached to a claim about people is a citation that does not reach the claim.

Are affiliate and creator claims our problem?

Yes. What a testimonial or endorsement conveys to a reasonable reader counts as the advertiser's own claim, and the substantiation obligation travels with it.

Does a disclaimer solve a substantiation problem?

No. A disclaimer addresses what a product is claimed to be for. It does not supply missing evidence for a claim that was made, and the governing question is the net impression the material creates for a reasonable reader.

Is this legal advice?

No. It is a reading of published FTC guidance with links to the source. Anything touching your specific circumstances belongs with qualified counsel.

Where this fits

The intended use question is covered in what Research Use Only actually means, which explains why marketing language rather than labeling determines what your product legally is. The enforcement record behind both tracks is examined in what FDA warning letters actually say. The distinction that governs which evidence supports which claim is set out in preclinical or human evidence.

All compounds referenced anywhere on this site are supplied strictly for laboratory research purposes only. Nothing here is for human consumption, and nothing here is intended to diagnose, treat, cure, or prevent any disease.